In the several years since Ozempic was approved by the FDA, there have been adverse event reports of Ozempic-related gastroparesis, stomach paralysis, and intestinal blockage cases in patients using Ozempic. Gastroparesis may also be called delayed gastric emptying. Gastroparesis is a long-term, chronic condition that can be irreversible even after a patient stops using Ozempic.
We point out that the current drug label for Ozempic does not warn about gastroparesis, stomach paralysis, and intestinal blockages or obstructions being potential side effects of Ozempic. As a result, patients are likely unaware that they are at risk for developing one of these severe gastric side effects, which can require hospitalization and surgery to treat.
Wegovy is a higher-dose version of Ozempic that is FDA-approved to treat obesity. Both of these relatively new drugs, from the pharmaceutical company Novo Nordisk, contain the active ingredient semaglutide. Wegovy has been linked to cases gastroparesis, stomach paralysis, and intestinal blockage, also. However, the current drug label for Wegovy (like Ozempic) does not warn about these severe gastric side effects.
We are investigating possible Wegovy and Ozempic drug injury lawsuits filed against Novo Nordisk based on this failure to warn doctors about those serious stomach or intestinal side effects. These Wegovy and Ozempic lawsuits involve gastroparesis, stomach paralysis, intestinal blockage, or intestinal blockage diagnosed in a patient while using Ozempic or Wegovy.[Read article in full at original source]
Strictly Confidential, No Obligation